Form 4: ZyVersa Therapeutics CCO Karen Cashmere Granted 48,100 Stock Options Amid Late Filing

ZyVersa Therapeutics, Inc.'s Chief Commercial Officer, Karen A. Cashmere, was granted 48,100 stock options with an exercise price of $0.59, vesting over three years, though the Form 4 filing was delayed due to an administrative oversight.

Summary

• Karen A. Cashmere, Chief Commercial Officer of ZyVersa Therapeutics, Inc. (ZVSA), was granted 48,100 stock options.
• The options have an exercise price of $0.59 per share.
• The grant date for these options was July 11, 2025.
• The options will vest in equal annual installments on the first three anniversaries of the grant date, contingent on continued service.
• The options have an expiration date of July 11, 2035.
• The Form 4 filing, reporting this transaction, was submitted late due to an inadvertent administrative oversight.

Sentiment

Score: 6

Explanation: The grant of options is a positive incentive for an executive, but the late filing due to an administrative oversight introduces a minor negative aspect regarding compliance.

Positives

• The grant of 48,100 stock options to the Chief Commercial Officer aligns her incentives with shareholder value creation.
• The options have a 10-year expiration period, providing a long-term incentive for the executive.

Negatives

• The Form 4 filing was submitted late, attributed to an inadvertent administrative oversight, indicating a lapse in internal compliance procedures.

Risks

• An inadvertent administrative oversight led to the late filing of a required SEC Form 4, which could indicate minor internal control weaknesses regarding regulatory compliance.

Future Outlook

The granted stock options will vest in equal annual installments over the first three anniversaries of the July 11, 2025 grant date, contingent on the Chief Commercial Officer's continued service.

Management Comments

• "This Form 4 is being filed late as the result of an inadvertent administrative oversight."

Industry Context

This filing is a routine disclosure of executive compensation in the biotechnology/pharmaceutical industry, where stock options are a common incentive for retaining and motivating key personnel.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options aims to align the Chief Commercial Officer's interests with shareholder value creation, potentially benefiting shareholders if the company's stock price increases. The late filing is a minor compliance issue.
• Employees: The grant is specific to one executive and does not directly impact other employees, though it reflects the company's executive compensation strategy.

Next Steps

• The stock options will vest in equal annual installments on the first three anniversaries of the July 11, 2025 grant date.

Key Dates

Keywords

ZyVersa Therapeutics, ZVSA, Stock Options, SEC Form 4, Insider Trading, Executive Compensation, Karen A. Cashmere, Chief Commercial Officer, Equity Grant, Beneficial Ownership